Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma

被引：11

作者：

Bilac, Cemal ^{[1
]}

Muezzinoglu, Talha ^{[2
]}

Ermertcan, Aylin Tuerel ^{[1
]}

Kayhan, Tuba Celebi ^{[1
]}

Temeltas, Goekhan ^{[2
]}

Ozturkcan, Serap ^{[1
]}

Temiz, Peyker ^{[3
]}

机构：

[1] Celal Bayar Univ, Fac Med, Dept Dermatol, TR-45010 Manisa, Turkey

[2] Celal Bayar Univ, Fac Med, Dept Urol, TR-45010 Manisa, Turkey

[3] Celal Bayar Univ, Fac Med, Dept Pathol, TR-45010 Manisa, Turkey

来源：

CUTANEOUS AND OCULAR TOXICOLOGY | 2009年 / 28卷 / 02期

关键词：

Sorafenib; side effect; skin; erythema multiforme; KINASE INHIBITOR; AGENTS; THERAPY; UPDATE; SKIN;

D O I：

10.1080/15569520902915469

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Sorafenib is a new therapeutic agent being used in metastatic renal cell carcinoma, hepatocellular carcinoma, and malignant melanoma. The most frequently seen cutaneous side effects due to sorafenib are erythema, exfoliative dermatitis, acne vulgaris, and flushing. Folliculitis, eczema, and erythema multiforme are other, rare side effects of sorafenib. A 59-year-old man underwent left radical nephrectomy due to renal cell carcinoma 8 months ago, and after the operation he received immunochemotherapy and then sorafenib. On the third day of sorafenib therapy his lesions occurred. His dermatologic examination revealed multiple erythematous papules on his neck, arms, and legs and bullae and iris lesions on his palms and soles. He was diagnosed as having erythema multiforme. In the literature we found only 1 other erythema multiforme case due to sorafenib. We present this interesting case to show and discuss cutaneous side effects of sorafenib, especially erythema multiforme as a very rare cutaneous side effect.

引用

页码：90 / 92

页数：3

共 10 条

[1] Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents [J].

Bellmunt, Joaquim ;

Montagut, Clara ;

Albiol, Santiago ;

Carles, Joan ;

Maroto, Pablo ;

Orsola, Anna .

BJU INTERNATIONAL, 2007, 99 (02) :274-280

[2]

FALCO OB, 2000, DERMATOLOGY, P571

[3] Chemotherapeutic agents and the skin: An update [J].

Heidary, Noushin ;

Naik, Haley ;

Burgin, Susan .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (04) :545-570

[4] Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor [J].

Lacouture, M. E. ;

Desai, A. ;

Soltani, K. ;

Petronic-Rosic, V. ;

Laumann, A. E. ;

Ratain, M. J. ;

Stadler, W. M. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2006, 31 (06) :783-785

[5] Sorafenib-induced erythema multiforme [J].

MacGregor, Jennifer L. ;

Silvers, David N. ;

Grossman, Marc E. ;

Sherman, William H. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (03) :527-528

[6] Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib [J].

Porta, C. ;

Paglino, C. ;

Imarisio, I. ;

Bonomi, L. .

CLINICAL AND EXPERIMENTAL MEDICINE, 2007, 7 (04) :127-134

[7] Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma [J].

Ratain, Mark J. ;

Eisen, Tim ;

Stadler, Walter M. ;

Flaherty, Keith T. ;

Kaye, Stan B. ;

Rosner, Gary L. ;

Gore, Martin ;

Desai, Apurva A. ;

Patnaik, Amita ;

Xiong, Henry Q. ;

Rowinsky, Lric ;

Abbruzzese, James L. ;

Xia, Chenghua ;

Simantov, Ronit ;

Schwartz, Brian ;

O'Dwyer, Peter J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2505-2512

[8] Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? [J].

Robert, C ;

Faivre, S ;

Raymond, E ;

Armand, JP ;

Escudier, B .

ANNALS OF INTERNAL MEDICINE, 2005, 143 (04) :313-314

[9] Cutaneous side-effects of kinase inhibitors and blocking antibodies [J].

Robert, C ;

Soria, JC ;

Spatz, A ;

Le Cesne, A ;

Malka, D ;

Pautier, P ;

Wechsler, J ;

Lhomme, C ;

Escudier, B ;

Boige, V ;

Armand, JP ;

Le Chevalier, T .

LANCET ONCOLOGY, 2005, 6 (07) :491-500

[10] Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy [J].

Yang, C-H. ;

Lin, W-C. ;

Chuang, C-K. ;

Chang, Y-C. ;

Pang, S-T. ;

Lin, Y-C. ;

Kuo, T-T. ;

Hsieh, J-J. ;

Chang, J. W. C. .

BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) :592-596

← 1 →